Form 8-K · Current Report · Filed 2026-02-26
Boston Scientific Enters New Revolving Credit Agreement
On February 26, 2026, Boston Scientific Corporation entered into a new $3.000 billion revolving credit agreement, a $2.000 billion 364-day revolving credit agreement, and a $6.000 billion term loan credit agreement.
- Filer
- Boston Scientific Corporation BSX · NYSE
- Filed
- Accession
- 0000885725-26-000017
- CIK
- 0000885725
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
These agreements replace a prior $2.000 billion revolving credit agreement from 2021, which was terminated on the same date. The new agreements provide various credit facilities with different terms and conditions, including interest rates, fees, and financial covenants. A copy of each agreement is attached as an exhibit to this filing.
Items reported
Reported Item
Market reaction
Close before filing
$73.48
Next session
+4.6%
Since filing
-36.4%
Latest close
$46.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BSX reporting the same item, with the next session's move:
About Boston Scientific Corporation
Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.
Never miss another BSX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.